Mesoblast Limited (MESO) AI Stock Analysis

Mesoblast Limited is a Melbourne, Australia-based regenerative medicine company operating internationally across Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company develops therapeutics using its proprietary platform centered on mesenchymal lineage cells. Its lead candidate, Remestemcel-L, is being evaluated in Phase III trials for conditions including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, biologic refractory inflammatory bowel disease, chronic heart failure, and chronic low back pain. Additional pipeline candidates include MPC-300-IV for rheumatoid arthritis and diabetic nephropathy, and MPC-25-IC for acute myocardial infarction. Mesoblast maintains strategic collaborations with Tasly Pharmaceutical Group, JCR Pharmaceuticals Co. Ltd., and Grunenthal.

Mesoblast's revenue rose from $10.2M in FY2022 to $120.8M in FY2026, generating a five-year revenue compound annual growth rate of 74.5% from FY2021 to FY2026. Following annual revenue declines of 26.5% in FY2023 to $7.5M and 21.3% in FY2024 to $5.9M, top-line growth accelerated 191.4% in FY2025 to $17.2M and 602.3% in FY2026. Gross margin turned positive to 70.2% in FY2025 and reached 84.1% in FY2026. Net losses narrowed from -$102.1M in FY2025 to -$57.8M in FY2026, with net margin improving to -47.8%. Research and development expenses grew to $97.9M in FY2026, while quarterly revenue growth reached 390.7% year-over-year for the quarter ending June 30, 2026.

As of June 30, 2026, Mesoblast held $102.9M in cash and short-term investments against total debt of $127.3M, resulting in net debt of $24.4M. Shareholders' equity stood at $568.4M on total assets of $773.1M. The company reported a current ratio of 2.43 and a debt-to-equity ratio of 0.22. Cash flow from operations was -$43.8M in FY2026, leading to free cash flow of -$44.7M after capital expenditures of $898,000. Over the past five years, the company's share count increased 100.2%.

Mesoblast closed at $13.28 on October 16, 2026, giving it a market capitalization of $1.72B and an enterprise value of $2.09B. The stock trades at a price-to-sales multiple of 14.3x and an enterprise value-to-revenue multiple of 17.4x, well above the median of its US-listed Healthcare peers of 4.1x price-to-sales. Its forward price-to-earnings ratio is 454.5x, compared to the peer median of 17.3x. Mesoblast's shares fell 26.6% over the trailing 12 months, trailing the S&P 500 benchmark return of 16.8%. Over five years, the stock generated a 16.9% gain versus 83.0% for the benchmark.

Wall Street coverage includes 1 Strong Buy and 2 Buy ratings, with zero Hold or Sell recommendations. The mean analyst price target is $37.00, representing 178.6% upside over the last close of $13.28. Consensus forecasts project revenue of $267.6M and an EPS of -$0.06 for the fiscal year ending June 30, 2027. For the following fiscal year, 2 analysts expect revenue to rise 58.7% to $424.8M with positive EPS of $0.46. Mesoblast beat EPS expectations in each of the last 4 quarters.

This page is an AI-written research summary of Mesoblast Limited (MESO). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MESO income statement, MESO balance sheet, MESO key metrics, MESO analyst forecast, MESO chart. See the MESO stock overview for the latest quote and news.